NCT05687123View on ClinicalTrials.gov

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

December 14, 2026

Study Completion Date

December 14, 2026

Conditions
Metastatic Pancreatic Neuroendocrine TumorPancreatic NeoplasmStage III Pancreatic Neuroendocrine Tumor AJCC v8Stage IV Pancreatic Neuroendocrine Tumor AJCC v8Unresectable Pancreatic Neuroendocrine Tumor
Interventions
PROCEDURE

Biospecimen Collection

Undergo a blood sample collection

PROCEDURE

Computed Tomography

Undergo a CT scan

DRUG

Lutetium Lu 177 Dotatate

Given IV

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo a SSR PET/CT scan

DRUG

Sunitinib Malate

Given PO

Trial Locations (9)

62269

RECRUITING

Memorial Hospital East, Shiloh

63110

RECRUITING

Washington University School of Medicine, St Louis

63129

RECRUITING

Siteman Cancer Center-South County, St Louis

63136

RECRUITING

Siteman Cancer Center at Christian Hospital, St Louis

63141

RECRUITING

Siteman Cancer Center at West County Hospital, Creve Coeur

63376

RECRUITING

Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters

91010

ACTIVE_NOT_RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

92868

RECRUITING

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

M5G 2M9

ACTIVE_NOT_RECRUITING

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH